Introduction
morning sickness, anxiety, nausea and vomiting, CINV, chemotherapy-induced nausea and vomiting
ONCOLOGY, MOTION SICKNESS, SECONDARY, CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
Olanzapine is an atypical antipsychotic drug that has been shown to be effective against chemotherapy-induced nausea and vomiting (CINV).Two double-blind, placebo-controlled phase 3 randomized clinical trials showed that olanzapine combined with triplet antiemetic therapy significantly improved nausea and vomiting compared with triplet therapy alone.The combination of 5 to 10 mg of olanzapine with triplet therapy is listed as a standard antiemetic therapy for HEC in the updated antiemetic guideline of the American Society of Clinical Oncology.Studies have reported that CINV has treatment-related (eg, type and dose of anticancer drugs) and patient-related (eg, young age, female sex, motion sickness experience, morning sickness experience during pregnancy, anxiety, no drinking habit, and history of CINV) risk factors.Since, to our knowledge, the J-FORCE was the largest randomized clinical trial of the efficacy of olanzapine, we hypothesized that a secondary analysis of this study could provide important information on the effectiveness of olanzapine for CINV with HEC, including cisplatin. In this preplanned secondary analysis of the J-FORCE trial results, we aimed to examine the add-on effect of olanzapine according to risk factors for CINV.